Xinhua/Wang Ying/ Getty Images Exact Sciences soared as much as 33% on Tuesday after it announced it would acquire Thrive Earlier Detection for up to $2.15 billion.Thrive Earlier Detection is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease.The deal will include an upfront payment of $1.7 billion in stock and cash, and up to an additional $450 million in potential milestone payments.In addition, Exact Sciences said it acquired Base Genomics for $410 million to expand its diagnostics technology.Visit the Business Insider homepage for more stories.Exact Sciences soared as much as 33% on Tuesday to record highs after the diagnostics company said it would acquire Thrive Earlier Detection for up to $2.15 billion in a stock and cash deal.Thrive Earlier Detection is a diagnostics company developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease.